Laura J van 't Veer, Ph.D. on MINDACT: Who Can Benefit From This? #ASCO2020 @UCSFMedicine

Laura J van 't Veer, Ph.D. on MINDACT: Who Can Benefit From This? #ASCO2020 @UCSFMedicine

User Photo
Cancer-News

4 months
132 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 1
Category:
Description:

Prof. Laura Van 'T Veer, Ph.D., Cheif Research Officer (CRO) and Co-Founder of Agendia and UCSF Helen Diller Family Cancer Center @UCSFMedicine discusses MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients presented at this year's virtual ASCO.

Read here: https://meetinglibrary.asco.org/record/184901/abstract

Up Next Autoplay
>